Yan Ding is an accomplished professional with extensive experience in pharmaceutical research and development. Currently serving as Director at Eli Lilly and Company since January 2022, Yan Ding develops pipelines for analyzing sequence data from next-generation sequencing platforms to support gene therapy quality control. Previous roles include contributions as a Research Scientist and Principal Research Scientist at Eli Lilly, where Yan Ding provided informatics support across multiple therapeutic areas, including oncology and metabolism, utilizing translational research methods. Earlier career highlights include a postdoctoral fellowship at the Van Andel Institute focused on RNAseq analysis for cancer research, and a Senior Research Scientist role at AbbVie, where Yan Ding supported clinical antibody-drug conjugate projects. Yan Ding obtained a Ph.D. in Pharmacology from the Chinese Academy of Medical Sciences.
This person is not in the org chart
This person is not in any teams
This person is not in any offices